JNK Inhibitor II Bulk

Biochem/physiol Actions

Reversible: yes

Product competes with ATP.

Primary TargetJNK 1, JNK 2, JNK 3

Target IC₅₀: 40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3

Cell permeable: yes

General description

A potent, cell-permeable, selective, and reversible inhibitor of c-Jun N-terminal kinase (JNK) (IC₅₀ = 40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3). The inhibition is competitive with respect to ATP. Exhibits over 300-fold greater selectivity for JNK as compared to ERK1 and p38-2 MAP kinases. Inhibits the phosphorylation of c-Jun and blocks cellular expression of IL-2, IFN-γ, TNF-α, and COX-2. Blocks IL-1-induced accumulation of phospho-Jun and induction of c-Jun transcription. A 50 mM (5 mg/454 µl) solution of JNK Inhibitor II (Cat. No. 420128) in DMSO is also available.

A potent, cell-permeable, selective, and reversible inhibitor of c-Jun N-terminal kinase (JNK) (IC₅₀ = 40 nM for JNK-1 and JNK-2 and 90 nM for JNK-3). The inhibition is competitive with respect to ATP. Exhibits over 300-fold greater selectivity for JNK as compared to ERK1 and p38-2 MAP kinases. Inhibits the phosphorylation of c-Jun and blocks the expression of IL-2, IFN-γ, TNF-α, and COX-2 in cells. Blocks IL-1-induced accumulation of phospho-Jun and induction of c-Jun transcription.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Shin, M., and Boyd, Y.D. 2002. Biochim. Biophys. Acta1589, 311.Bennett, B.L., et al. 2001. Proc. Natl. Acad. Sci. USA98, 13681.Han, Z., et al. 2001. J. Clin. Invest.108, 73.

Packaging

Packaged under inert gas

5, 25, 50 mg in Plastic ampoule

Preparation Note

For every 10 µM concentration of JNK Inhibitor II, include 0.1% DMSO in the culture medium. Pre-warming of culture medium and addition of BSA to the medium may enhance its solubility.

Reconstitution

Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 2 months at -20°C.

Warning

Toxicity: Standard Handling (A)